The EPO published patent application EP3770177A1 titled 'Anti-PD-1 Monoclonal Antibodies and Obtaining Method thereof' for monoclonal antibodies targeting the PD-1 checkpoint pathway. Applicants are Beijing Dongfang Biotech Co., Ltd and Beijing Jingyitaixiang Technology Development Co., Ltd, both based in Beijing. The application covers methods of obtaining the antibodies and their use in treating cancer and immunological diseases, designated across 36 European Patent Convention states.\n\nCompanies developing PD-1/PD-L1 targeted immunotherapies should review this publication for potential freedom-to-operate implications. Patent prosecution will continue before potential grant; parties may consider monitoring the application or evaluating licensing needs. There are no immediate compliance deadlines associated with this patent publication.